{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:18:57Z","timestamp":1788153537679,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The triglyceride-glucose (TyG) index is a simple surrogate marker of insulin resistance. Whether baseline fatty liver modifies the association between TyG and incident hypertension has not been evaluated in large longitudinal cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 66,664 adults without hypertension at baseline who underwent routine health examinations and follow-up. The TyG index was calculated from fasting triglyceride and fasting glucose concentrations and analyzed as both a continuous and categorical variable. Baseline fatty liver status was assessed by abdominal ultrasonography. Participants were followed for a median of 2.37 years (interquartile range, 1.69-3.21 years). Multivariable Cox proportional hazards models adjusted for age, sex, marital status, ethnicity, body mass index, lifestyle factors, cholesterol measures, and liver enzymes were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Effect modification by fatty liver status was evaluated using stratified analyses and a TyG-by-fatty liver interaction term. Joint associations of TyG category and fatty liver status with new-onset hypertension were also examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During follow-up, 13,949 (20.9%) participants developed new-onset hypertension. Higher TyG was independently associated with new-onset hypertension as a continuous variable (HR 1.37, 95% CI 1.30-1.45) and in the highest versus lowest quartile (HR 1.61, 95% CI 1.49-1.75). Participants with both high TyG and fatty liver had the highest risk (HR 1.63, 95% CI 1.52-1.76), and fatty liver significantly modified the TyG-hypertension association (P for interaction &amp;lt;0.001). These associations remained materially unchanged in sensitivity analyses with additional adjustment for family history of hypertension, diabetes status, kidney function, and baseline blood pressure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher baseline TyG and fatty liver were associated with an increased risk of new-onset hypertension. Baseline fatty liver modified the association between TyG and new-onset hypertension. These findings may help inform the interpretation of TyG-related future hypertension risk according to baseline fatty liver status among adults undergoing routine health examinations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1897050","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:39Z","timestamp":1788150579000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect modification by fatty liver in the association between triglyceride-Glucose index and new-onset hypertension: a large health-examination cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuzhan","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, The Third Affiliated Hospital of Wenzhou Medical University","place":["Ruian, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Third Affiliated Hospital of Wenzhou Medical University","place":["Ruian, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaorong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Third Affiliated Hospital of Wenzhou Medical University","place":["Ruian, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Third Affiliated Hospital of Wenzhou Medical University","place":["Ruian, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02208-1","article-title":"WHO global report on hypertension 2025","volume":"406","author":"Farrar","year":"2025","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.37.12.1595","article-title":"Banting lecture 1988. Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.14.3.173","article-title":"Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease","volume":"14","author":"DeFronzo","year":"1991","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","article-title":"The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects","volume":"6","author":"Simental-Mend\u00eda","year":"2008","journal-title":"Metab Syndr Relat Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0288","article-title":"The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp","volume":"95","author":"Guerrero-Romero","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12944-017-0562-y","article-title":"Triglyceride and glucose (TyG) index as a predictor of incident hypertension: a 9-year longitudinal population-based study","volume":"16","author":"Zheng","year":"2017","journal-title":"Lipids Health Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12933-022-01511-x","article-title":"Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations","volume":"21","author":"Tao","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"For the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15220","article-title":"Nonalcoholic fatty liver disease and advanced fibrosis in US adults across blood pressure categories","volume":"76","author":"Ciardullo","year":"2020","journal-title":"Hypertension"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.01.009","article-title":"Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension","volume":"60","author":"Sung","year":"2014","journal-title":"J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01526.x","article-title":"The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation","volume":"102","author":"Hamaguchi","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12933-023-01795-7","article-title":"Positive association of triglyceride-glucose index with new-onset hypertension among adults: a national cohort study in China","volume":"22","author":"Gao","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.644035","article-title":"Association between triglyceride-glucose index and hypertension: a meta-analysis","volume":"8","author":"Wang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12944-023-01925-w","article-title":"Triglyceride-glucose index is associated with hypertension incidence up to 13 years of follow-up in mexican adults","volume":"22","author":"Argoty-Pantoja","year":"2023","journal-title":"Lipids Health Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s44197-024-00269-7","article-title":"Triglyceride-glucose index as predictor for hypertension, CHD and STROKE risk among non-diabetic patients: a NHANES cross-sectional study 2001-2020","volume":"14","author":"Sawaf","year":"2024","journal-title":"J Epidemiol Glob Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.02.066","article-title":"Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited","volume":"36","author":"da Silva","year":"2020","journal-title":"Can J Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12933-021-01342-2","article-title":"Association between triglyceride-glucose index and risk of arterial stiffness: a cohort study","volume":"20","author":"Wu","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8463640","article-title":"Bidirectional association between hypertension and NAFLD: a systematic review and meta-analysis of observational studies","volume":"2022","author":"Li","year":"2022","journal-title":"Int J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-024-01708-5","article-title":"Temporal relationship between hepatic steatosis and blood pressure elevation and the mediation effect in the development of cardiovascular disease","volume":"47","author":"Hu","year":"2024","journal-title":"Hypertens Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2023.04.021","article-title":"Nonalcoholic fatty liver disease and risk of incident young-onset hypertension: effect modification by sex","volume":"33","author":"Kim","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002111","article-title":"Severity of non-alcoholic fatty liver disease is a risk factor for developing hypertension from prehypertension","volume":"136","author":"Song","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence","volume":"68","author":"Lonardo","year":"2017","journal-title":"J Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/life12050718","article-title":"Endothelial dysfunction in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Theofilis","year":"2022","journal-title":"Life (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2025.2471871","article-title":"Arterial stiffness as a complication of metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"19","author":"Giannakodimos","year":"2025","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1119005","article-title":"The regulatory role of metabolic organ-secreted factors in the nonalcoholic fatty liver disease and cardiovascular disease","volume":"10","author":"Qin","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12944-018-0913-3","article-title":"A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease","volume":"17","author":"Zheng","year":"2018","journal-title":"Lipids Health Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043169","article-title":"The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: a dose-response meta-analysis","volume":"13","author":"Ling","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00535-024-02093-z","article-title":"Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease","volume":"59","author":"Wakabayashi","year":"2024","journal-title":"J Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1897050\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:40Z","timestamp":1788150580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1897050\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":34,"alternative-id":["10.3389\/fendo.2026.1897050"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1897050","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1897050"}}